Loading
We have very little insider data for Zenith Epigenetics Corp. so far: the most recent filing dates from 19 June 2016. With so few records, no pattern can be drawn yet. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
23 of 23 declarations
Zenith Epigenetics Corp. is a company focused on developing epigenetic therapies for cancer treatment. It is listed on the Toronto Stock Exchange (XTSE).